Proactive Investors - Run By Investors For Investors

Tumour Trace device 'just makes sense' - Lancor's chief medical officer

Lancor Scientific's chief operating officer Gopal Rao and chief medical officer Roland Schlesinger discuss with Proactive Investors some of the upcoming milestones for their Tumour Trace technology.

Roland Schlesinger's a specialist in health technology assessment - essentially analysing pharmaceuticals or medical technologies for efficiency and efficacy.

''The great thing about the technology is that we're looking for  a quantifiable biomarker in the tissue - the hugely exciting thing about that is we're looking for a primary cancer, not a metastatic one, which means we're not catching it late we're very much catching it both early and even pre-early'', Rao says.

''We are absolutely able to reach an accuracy level of 98% definitely .... compared to others that are around 73-78%%'', Schlesinger says.

He adds: ''Also the time is very important - most procedures take days .. however with us we have results in less than three minutes''.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here  
View full LANCO profile View Profile

Lancor Scientific Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use